Eton Pharmaceuticals Overview
Latest ROE for Eton Pharmaceuticals: 27.24% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow27.24%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ETON is 27.24%. That is above the Healthcare sector average of 20.86%. Investors often review this figure alongside Eton Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ETON currently prints 27.24% for ROE, while the sector average sits near 20.86%. That is roughly 30.6% above the sector mean. Large gaps often invite a closer look at Eton Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively Eton Pharmaceuticals converts resources into returns. At 27.24%, ETON may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ETON's ROE (27.24%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Eton Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
